# Core 2: Biocontainment and Immune Monitoring Core

> **NIH NIH P01** · DUKE UNIVERSITY · 2021 · $2,468,103

## Abstract

Core 2: Biocontainment and Immune Monitoring
Abstract
The overall goal of this program is to develop a vaccine or vaccines that will be available when the next
betaCoV outbreak occurs. In support of this overall goal, a Biocontainment and Immune Monitoring Core
has been centralized at Duke. The Core is comprised of technologies and services offered through the Duke
Regional Biocontanment Laboratory (Duke RBL), the Duke Human Vaccine Institute (DHVI) Flow Cytometry
and Cell Sorting facility, and the Montefiori and Ferrari antibody characterization laboratories. The Duke RBL
is one of 12 NIH-constructed RBLs, and was the first to begin operation in 2007. The Duke RBL provides an
administrative umbrella for safe, secure and compliant BSL2-3/ABSL2-3 and Select Agent research activities
at Duke University. The Duke RBL has state-of-the-art BSL3 biocontainment laboratory modules, high-
containment cell sorting, a portfolio of service units (i. e. Microbiology, Virology, Immunology and Animal
Models Support), an integrated ABSL3 vivarium to support small animal challenge models, and was purpose
built to support the development of diagnostics, therapeutics and vaccines for emerging/reemerging infections
and biodefense. The Core will routinely provide program investigators with high-containment cell sorting and
comprehensive phenotyping, multiplex biomarker profiling, viral load, neutralization and antibody-dependent
cellular cytotoxicity assays, and small animal SARS-CoV-2 challenge models. Critical to all five Core
Aims/Tasks is a commitment to ongoing quality control of instruments and assays; and a strong commitment to
anticipate and meet the needs of all four projects and the NHP Core. By educating and working in
collaboration with program investigators we will optimize assays to meet their needs and more effectively
utilize the state-of-the-art instrumentation and biocontainment facilities available through the Biocontaniment
and Immune Monitoring Core. Comprehensive and centralized immune monitoring by a team with a proven
track-record will add value to all proposed studies, and will allow project investigators to better, and more
efficiently, design and develop panbetaCoV vaccines.

## Key facts

- **NIH application ID:** 10327521
- **Project number:** 1P01AI158571-01A1
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Gregory D Sempowski
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,468,103
- **Award type:** 1
- **Project period:** 2021-09-16 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10327521

## Citation

> US National Institutes of Health, RePORTER application 10327521, Core 2: Biocontainment and Immune Monitoring Core (1P01AI158571-01A1). Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/grant/nih/10327521. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*